Developing reagents to noninvasively visualize and quantify NRP expression levels will create new opportunities for imaging glioma, documenting tumor receptor expression, and more appropriately selecting patients to be considered for anti-NRP treatment. This evidence concerns the gene NRP1 and central nervous system cancer.